Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE Cash Ratio is 6.58 as of Dec. 2025, which is 91% above its 10-year median of 3.45. The stock has 2 warning signs investors should review. Among 1,381 Biotechnology companies, Avecho Biotechnology ranks better than 69.8% on this metric.
Avecho Biotechnology has a Cash Ratio of 6.58. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Avecho Biotechnology's Cash Ratio or its related term are showing as below:
ASX:AVE'
s Cash Ratio Range Over the Past 10 Years
Min: 1.31 Med: 3.45 Max: 6.58
Current: 6.58
During the past 13 years, Avecho Biotechnology's highest Cash Ratio was 6.58. The lowest was 1.31. And the median was 3.45.
ASX:AVE's Cash Ratio is ranked better than 69.8% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs ASX:AVE: 6.58
Avecho Biotechnology (ASX:AVE) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Avecho Biotechnology Cash Ratio Related Terms
Avecho Biotechnology Cash Ratio Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVE vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Avecho Biotechnology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology (ASX:AVE) has a Cash Ratio of 6.58 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avecho Biotechnology and its competitors. This is 91% above median its historical median of 3.45. Over the past decade, Avecho Biotechnology's Cash Ratio has ranged from 1.31 to 6.58. According to the industry distribution chart, Avecho Biotechnology ranks #417 out of 1381 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Avecho Biotechnology's Cash Ratio too high?
Avecho Biotechnology's current Cash Ratio of 6.58 is 91% above median its 10-year median of 3.45. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 6.58. The Biotechnology industry median Cash Ratio is 2.96. Avecho Biotechnology's value of 6.58 is 122.3% above this industry median. Based on the distribution chart, Avecho Biotechnology ranks #417 out of 1381 companies in the Biotechnology industry, which is above the industry midpoint.
How does Avecho Biotechnology's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #417 out of 1381 companies for Cash Ratio. This puts Avecho Biotechnology in the upper half of its industry. The industry median Cash Ratio is 2.96. Avecho Biotechnology's value of 6.58 is 122.3% above this benchmark. Historically, Avecho Biotechnology's own Cash Ratio has ranged from 1.31 to 6.58 over the past decade. While the company's 10-year median is 3.45 vs. the industry median of 2.96, Avecho Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avecho Biotechnology's current Cash Ratio of 6.58 is 122.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avecho Biotechnology and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current Cash Ratio is 6.58, which is 91% above median its own 10-year median of 3.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Cash Ratio of 6.58. The current Cash Ratio is 6.58, which is 91% above median its 10-year median of 3.45 and 122.3% above the Biotechnology industry median of 2.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Cash Ratio is 6.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
